Standard BioTools Inc.
Standard BioTools Inc. (LAB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lab · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Standard BioTools Inc. (LAB) measures how much investors pay for each dollar of the company's trailing earnings. LAB's current PE ratio of N/A is calculated by dividing its stock price of $0.80 by its TTM earnings per share of -$0.24.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Standard BioTools Inc.You LAB | $314M | N/A | — | -$0.24 |
 ADC Therapeutics S.A. ADCT | $124M | N/A | — | -$1.12 |
 Avanos Medical, Inc. AVNS | $1.2B | N/A | — | -$1.46 |
 Bioventus Inc. BVS | $606M | 21.81x | — | $0.34 |
 CeriBell, Inc. CBLL | $688M | N/A | — | -$1.46 |
 Cullinan Therapeutics, Inc. CGEM | $816M | N/A | — | -$3.72 |
 Cytek Biosciences, Inc. CTKB | $522M | N/A | — | -$0.52 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.20 | — | |
2024-12-31 FY2024 | — | $-0.39 | — | |
2023-12-31 FY2023 | — | $-0.94 | — | |
2022-12-31 FY2022 | — | $-2.43 | — | |
2021-12-31 FY2021 | — | $-0.78 | — | |
2020-12-31 FY2020 | — | $-0.74 | — | |
2019-12-31 FY2019 | — | $-0.97 | — | |
2018-12-31 FY2018 | — | $-1.49 | — | |
2017-12-31 FY2017 | — | $-1.84 | — | |
2016-12-31 FY2016 | — | $-2.62 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Standard BioTools Inc. (LAB) measures how much investors pay for each dollar of the company's trailing earnings. LAB's current PE ratio of N/A is calculated by dividing its stock price of $0.80 by its TTM earnings per share of -$0.24.
Frequently asked questions
LAB pe ratio · 6 questionsLAB's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.80 and TTM EPS of -$0.24. Data sourced from Financial Modeling Prep via LAB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Standard BioTools Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08